<a href="https://laohu8.com/S/002422">Sichuan Kelun</a> Biotech receives NMPA approval for third indication of TROP2 ADC sac TMT in EGFR mutant NSCLC after EGFR TKI therapy
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. has announced that its TROP2-directed antibody-drug conjugate, sacituzumab tirumotecan (sac-TMT, also known as SKB264/MK-2870), has received marketing approval from the National Medical Products Administration (NMPA) for its third indication. The newly approved use is for the treatment of adult patients with EGFR mutant-positive locally advanced or metastatic non-squamous non-small cell lung cancer (NSCLC) who have progressed after EGFR-tyrosine kinase inhibitor (TKI) therapy. This approval is based on positive results from the Phase III OptiTROP-Lung04 study, which demonstrated significant improvements in overall survival and progression-free survival compared to platinum-based chemotherapy in this patient population. No grant or funding information involving multiple organizations was mentioned.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. published the original content used to generate this news brief via PR Newswire (Ref. ID: CN95771) on October 11, 2025, and is solely responsible for the information contained therein.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。